Subscribe to RSS
DOI: 10.1055/s-0042-1756172
New Seminars in Thrombosis and Hemostasis (STH) 2021 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics
![](https://www.thieme-connect.de/media/sth/202206/lookinside/thumbnails/10-1055-s-0042-1756172_03031-1.jpg)
This Editorial continues our deviation from our historical approach, which typically announced our newest Journal Impact Factor (IF) and other journal metrics as part of our yearly welcome editorial. This change reflects the recognition of the tendency to access online material well ahead of the print publication date. Accordingly, this Editorial update is being published before our standard yearly Welcome Editorial, which always publishes with the first issue of the year. As I did on the last occasion, then announcing the 2020 IF,[1] I am again sharing additional journal metrics with the readership.
Publication History
Article published online:
12 October 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Favaloro EJ. New STH (2020) Impact Factor, Most Highly Cited Papers, and Other Journal Metrics. Semin Thromb Hemost 2021; 47 (07) 745-753
- 2 COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. (JHU). Accessed July 3, 2022 at: https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6
- 3 National Library of Medicine/National Center for Biotechnology Information/PubMed.com. Accessed July 3, 2022 at: https://pubmed.ncbi.nlm.nih.gov/?term=covid-19
- 4 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part I. Semin Thromb Hemost 2020; 46 (07) 757-762
- 5 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): part II. Semin Thromb Hemost 2021; 47 (04) 333-337
- 6 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part III. Semin Thromb Hemost 2022; 48 (01) 3-7
- 7 Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: part I-most popular articles. Semin Thromb Hemost 2021; 47 (05) 467-476
- 8 Favaloro EJ. The Journal Impact Factor: don't expect its demise any time soon. Clin Chem Lab Med 2009; 47 (11) 1319-1324
- 9 Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. Semin Thromb Hemost 2008; 34 (01) 7-25
- 10 Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020; 46 (07) 763-771
- 11 Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019; 45 (07) 661-673
- 12 Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost 2019; 45 (01) 86-93
- 13 Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost 2020; 46 (01) 89-95
- 14 Kwaan HC, Lindholm PF. Fibrin and fibrinolysis in cancer. Semin Thromb Hemost 2019; 45 (04) 413-422
- 15 Hisada Y, Mackman N. Tissue factor and cancer: regulation, tumor growth, and metastasis. Semin Thromb Hemost 2019; 45 (04) 385-395
- 16 Arachchillage DR, Laffan M. Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms. Semin Thromb Hemost 2019; 45 (06) 604-611
- 17 Danese E, Montagnana M, Favaloro EJ, Lippi G. Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics. Semin Thromb Hemost 2020; 46 (03) 264-274
- 18 Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. Semin Thromb Hemost 2019; 45 (01) 22-35
- 19 Levi M. Disseminated intravascular coagulation in cancer: an update. Semin Thromb Hemost 2019; 45 (04) 342-347
- 20 Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. Semin Thromb Hemost 2020; 46 (03) 275-288
- 21 Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. Semin Thromb Hemost 2020; 46 (03) 302-319
- 22 Mahajan A, Brunson A, White R, Wun T. The epidemiology of cancer-associated venous thromboembolism: an update. Semin Thromb Hemost 2019; 45 (04) 321-325
- 23 DeLoughery EP, Olson SR, Puy C, McCarty OJT, Shatzel JJ. The safety and efficacy of novel agents targeting factors XI and XII in early phase human trials. Semin Thromb Hemost 2019; 45 (05) 502-508
- 24 Gosselin RC, Marlar RA. Preanalytical variables in coagulation testing: setting the stage for accurate results. Semin Thromb Hemost 2019; 45 (05) 433-448
- 25 Dvorak HF. Tumors: wounds that do not heal-a historical perspective with a focus on the fundamental roles of increased vascular permeability and clotting. Semin Thromb Hemost 2019; 45 (06) 576-592
- 26 Marongiu F, Mameli A, Grandone E, Barcellona D. Pulmonary thrombosis: a clinical pathological entity distinct from pulmonary embolism?. Semin Thromb Hemost 2019; 45 (08) 778-783
- 27 Konstantinidi A, Sokou R, Parastatidou S. et al. Clinical application of thromboelastography/thromboelastometry (TEG/TEM) in the neonatal population: a narrative review. Semin Thromb Hemost 2019; 45 (05) 449-457
- 28 Lippi G, Gosselin R, Favaloro EJ. Current and emerging direct oral anticoagulants: state-of-the-art. Semin Thromb Hemost 2019; 45 (05) 490-501
- 29 Lebreton A, Sinegre T, Lecompte T, Talon L, Abergel A, Lisman T. Thrombin generation and cirrhosis: state of the art and perspectives. Semin Thromb Hemost 2020; 46 (06) 693-703
- 30 Christensen B, Favaloro EJ, Lippi G, Van Cott EM. Hematology laboratory abnormalities in patients with coronavirus disease 2019 (COVID-19). Semin Thromb Hemost 2020; 46 (07) 845-849
- 31 Riedl J, Ay C. Venous thromboembolism in brain tumors: risk factors, molecular mechanisms, and clinical challenges. Semin Thromb Hemost 2019; 45 (04) 334-341
- 32 Tabibian S, Shiravand Y, Shams M. et al. A comprehensive overview of coagulation factor V and congenital factor V deficiency. Semin Thromb Hemost 2019; 45 (05) 523-543
- 33 Mege D, Aubert M, Lacroix R, Dignat-George F, Panicot-Dubois L, Dubois C. Involvement of platelets in cancers. Semin Thromb Hemost 2019; 45 (06) 569-575
- 34 Bastida JM, Benito R, Lozano ML. et al. Molecular diagnosis of inherited coagulation and bleeding disorders. Semin Thromb Hemost 2019; 45 (07) 695-707
- 35 Thiele T, Greinacher A. Platelet transfusion in perioperative medicine. Semin Thromb Hemost 2020; 46 (01) 50-61
- 36 Moore HB, Moore EE. Temporal changes in fibrinolysis following injury. Semin Thromb Hemost 2020; 46 (02) 189-198
- 37 Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC dipstick. Semin Thromb Hemost 2019; 45 (03) 275-284
- 38 Tawil N, Bassawon R, Rak J. Oncogenes and clotting factors: the emerging role of tumor cell genome and epigenome in cancer-associated thrombosis. Semin Thromb Hemost 2019; 45 (04) 373-384
- 39 Rondon AMR, Kroone C, Kapteijn MY, Versteeg HH, Buijs JT. Role of tissue factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 2019; 45 (04) 396-412
- 40 Sharma BK, Flick MJ, Palumbo JS. Cancer-associated thrombosis: a two-way street. Semin Thromb Hemost 2019; 45 (06) 559-568
- 41 Lacroix R, Vallier L, Bonifay A. et al. Microvesicles and cancer associated thrombosis. Semin Thromb Hemost 2019; 45 (06) 593-603
- 42 Black JA, Pierce VS, Kerby JD, Holcomb JB. The evolution of blood transfusion in the trauma patient: whole blood has come full circle. Semin Thromb Hemost 2020; 46 (02) 215-220
- 43 Hartmann J, Walsh M, Grisoli A. et al. Diagnosis and treatment of trauma-induced coagulopathy by viscoelastography. Semin Thromb Hemost 2020; 46 (02) 134-146
- 44 Roberts LN, Bernal W. Incidence of bleeding and thrombosis in patients with liver disease. Semin Thromb Hemost 2020; 46 (06) 656-664
- 45 Khemichian S, Terrault NA. Thrombopoietin receptor agonists in patients with chronic liver disease. Semin Thromb Hemost 2020; 46 (06) 682-692
- 46 Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: part I-most popular articles. Semin Thromb Hemost 2020; 46 (04) 383-392
- 47 Favaloro EJ. 2022 Eberhard F. Mammen Award Announcements: part I-most popular articles. Semin Thromb Hemost 2022; 48 (05) 502-513
- 48 Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or pulmonary embolism?. Semin Thromb Hemost 2020; 46 (07) 777-780
- 49 Levi M, Thachil J. Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both. Semin Thromb Hemost 2020; 46 (07) 781-784
- 50 Larsen JB, Pasalic L, Hvas AM. Platelets in coronavirus disease 2019. Semin Thromb Hemost 2020; 46 (07) 823-825
- 51 de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C. Impaired breakdown of bradykinin and its metabolites as a possible cause for pulmonary edema in COVID-19 infection. Semin Thromb Hemost 2020; 46 (07) 835-837
- 52 Schulman S. Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost 2020; 46 (07) 772-776
- 53 Kwaan HC. Coronavirus disease 2019: the role of the fibrinolytic system from transmission to organ injury and sequelae. Semin Thromb Hemost 2020; 46 (07) 841-844
- 54 Favaloro EJ, Lippi G. Recommendations for minimal laboratory testing panels in patients with COVID-19: potential for prognostic monitoring. Semin Thromb Hemost 2020; 46 (03) 379-382
- 55 Parra-Izquierdo I, Aslan JE. Perspectives on platelet heterogeneity and host immune response in coronavirus disease 2019 (COVID-19). Semin Thromb Hemost 2020; 46 (07) 826-830
- 56 Dorgalaleh A. Bleeding and bleeding risk in COVID-19. Semin Thromb Hemost 2020; 46 (07) 815-818
- 57 Thachil J, Lisman T. Pulmonary megakaryocytes in coronavirus disease 2019 (COVID-19): roles in thrombi and fibrosis. Semin Thromb Hemost 2020; 46 (07) 831-834
- 58 Vadasz Z, Brenner B, Toubi E. Immune-mediated coagulopathy in COVID-19 infection. Semin Thromb Hemost 2020; 46 (07) 838-840
- 59 Horowitz NA, Brenner B. Thrombosis and hemostasis issues in cancer patients with COVID-19. Semin Thromb Hemost 2020; 46 (07) 785-788
- 60 Coppola A, Tagliaferri A, Rivolta GF, Quintavalle G, Franchini M. Confronting COVID-19: issues in hemophilia and congenital bleeding disorders. Semin Thromb Hemost 2020; 46 (07) 819-822
- 61 Favaloro EJ. 2017 Eberhard F. Mammen award announcements: part II-young investigator awards. Semin Thromb Hemost 2018; 44 (02) 81-88
- 62 Kwaan HC, Lindholm PF. Emerging paradigms of thrombosis and cancer (part I): the yin yang relationship between thrombosis and cancer. Semin Thromb Hemost 2019; 45 (04) 319-320
- 63 Favaloro EJ, Lippi G. Editorial compilation VI. Semin Thromb Hemost 2019; 45 (01) 5-9
- 64 Favaloro EJ, Lippi G. Editorial compilation VII. Semin Thromb Hemost 2019; 45 (05) 429-432
- 65 Kwaan HC, Lindholm PF. Emergent paradigms of thrombosis and cancer (part II): more on thrombosis and cancer. Semin Thromb Hemost 2019; 45 (06) 557-558
- 66 Hvas AM, Larsen JB, Pasalic L. Acquired platelet dysfunction-laboratory and clinical implications. Semin Thromb Hemost 2020; 46 (03) 235-237
- 67 Rabbolini DJ, Othman M. Molecular and genetic testing in thrombosis and hemostasis. Semin Thromb Hemost 2019; 45 (07) 657-660
- 68 Favaloro EJA. 2018 update on the editorial and publication policy of seminars in thrombosis and hemostasis. Semin Thromb Hemost 2018; 44 (04) 307-311
- 69 Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930-2008). Semin Thromb Hemost 2008; 34 (08) 703-707
- 70 Favaloro EJ. A short history of thrombosis and hemostasis: part I (40th year celebratory issue). Semin Thromb Hemost 2014; 40 (05) 521-525
- 71 Favaloro EJ. A short history of thrombosis and hemostasis: part II (40th year celebratory issue). Semin Thromb Hemost 2014; 40 (08) 826-830